Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1382-1397
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1382
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1382
Table 1 Top canonical pathways for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis identified by Ingenuity Pathway Analysis
| Overlap | P value | |
| Top canonical pathways in NAFLD vs healthy control | ||
| Liver X receptor / retinoid X receptor activation | 5/121 | 4.35E-05 |
| Superpathway of cholesterol biosynthesis | 3/29 | 1.08E-04 |
| Granulocyte adhesion and diapedesis | 5/173 | 2.34E-04 |
| CREB signaling | 8/596 | 6.25E-04 |
| Mevalonate pathway I | 2/14 | 8.96E-04 |
| Top canonical pathways in NASH vs healthy control | ||
| Cholesterol biosynthesis I | 4/13 | 5.48E-05 |
| Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) | 4/13 | 5.48E-05 |
| Cholesterol biosynthesis III (via desmosterol) | 4/13 | 5.48E-05 |
| IGF-1 signaling | 9/106 | 9.16E-05 |
| Superpathway of cholesterol biosynthesis | 5/28 | 1.05E-04 |
- Citation: Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H, Segal M, Mukhtar M, Mohammed M, Panahiazar M, Hadley D, Spengler R, Spengler E. Transcriptome changes in stages of non-alcoholic fatty liver disease. World J Hepatol 2022; 14(7): 1382-1397
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1382.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1382